List of Excipients in Branded Drug QUELICIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	QUELICIN	succinylcholine chloride	0409-6629	HYDROCHLORIC ACID
Hospira Inc	QUELICIN	succinylcholine chloride	0409-6629	METHYLPARABEN
Hospira Inc	QUELICIN	succinylcholine chloride	0409-6629	PROPYLPARABEN
Hospira Inc	QUELICIN	succinylcholine chloride	0409-6629	SODIUM CHLORIDE
Hospira Inc	QUELICIN	succinylcholine chloride	0409-6629	SODIUM HYDROXIDE
Medical Purchasing Solutions LLC	QUELICIN	succinylcholine chloride	71872-7026	HYDROCHLORIC ACID

Quelicin Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Quelicin is a preservative-free, injectable formulation of succinylcholine chloride, a short-acting depolarizing neuromuscular blocker used for rapid tracheal intubation, skeletal-muscle relaxation, and emergency airway management. Its commercial value is driven less by molecule-level exclusivity than by sterile manufacturing reliability, ready-to-use presentation, hospital-contract access, shortage resilience, and differentiated packaging.

The core excipient system is simple: water for injection, sodium chloride for isotonicity, and pH adjustment with sulfuric acid and/or sodium hydroxide. That simplicity limits conventional formulation patent opportunities but creates opportunities in container closure, presentation, stability, pharmacy workflow, and supply assurance.

What is Quelicin and which excipients does it contain?

Quelicin contains succinylcholine chloride injection at a concentration of 20 mg/mL. The marketed product is supplied as a sterile, preservative-free solution for intravenous or intramuscular administration.

Attribute	Quelicin profile
Active ingredient	Succinylcholine chloride
Therapeutic class	Depolarizing neuromuscular blocker
Strength	20 mg/mL
Dosage form	Sterile injectable solution
Route	Intravenous or intramuscular
Primary excipients	Sodium chloride and water for injection
pH adjustment	Sulfuric acid and/or sodium hydroxide
Preservative	None in the labeled formulation
Primary use	Rapid sequence intubation and short-term skeletal-muscle paralysis
Regulatory pathway	FDA-approved prescription injectable
Biosimilar relevance	None; succinylcholine is a small-molecule drug

The label identifies each milliliter as containing 20 mg of succinylcholine chloride and 9 mg of sodium chloride, with water for injection. The solution pH is adjusted within the labeled acidic range using sulfuric acid and/or sodium hydroxide. Quelicin does not rely on a complex buffer, surfactant, cosolvent, or antimicrobial preservative system. [1]

Why is sodium chloride used in Quelicin?

Sodium chloride provides isotonicity and supports compatibility with parenteral administration. At 9 mg/mL, the formulation corresponds to a 0.9% sodium chloride environment, although the product should not be treated as interchangeable with a standard saline bag for dilution or administration without reference to the prescribing information and institutional procedures.

Why is Quelicin preservative-free?

The absence of an antimicrobial preservative reduces exposure to benzyl alcohol, parabens, phenol, and related excipient risks. That is commercially relevant in anesthesia, emergency medicine, neonatal care, and operating-room settings where preservative-free presentations are often preferred.

The tradeoff is greater dependence on aseptic manufacturing, single-use handling, container integrity, and hospital storage controls. Preservative-free products also create less flexibility for repeated vial entry than multidose preserved products.

What formulation is protected by Quelicin’s intellectual-property estate?

Quelicin has little apparent commercial protection from excipient composition. Succinylcholine was introduced decades ago, and the basic formulation of succinylcholine chloride in water with sodium chloride and pH adjustment is technically conventional.

IP category	Commercial assessment
Succinylcholine molecule	Long expired or otherwise outside meaningful exclusivity
Basic aqueous formulation	Low patentability and low differentiation
Sodium chloride isotonicity	Routine pharmaceutical practice
pH adjustment	Conventional manufacturing feature
Preservative-free presentation	Potentially differentiating, but generally difficult to protect broadly
Ready-to-use injectable format	Commercially valuable, usually weak as standalone patent subject matter
Container closure	Possible technical IP if tied to extractables, stability, or oxygen control
Manufacturing process	Potentially protectable when process-specific and non-obvious
Device or administration system	Potentially protectable separately from the drug formulation
Trade secrets	Important for sterile process controls, filling, inspection, and supply qualification

A formulation patent would need to establish a non-obvious technical effect, such as materially improved stability, reduced degradation, lower impurity formation, enhanced container compatibility, or improved usability. A claim limited to succinylcholine, sodium chloride, water, and pH adjustment would face substantial prior-art and obviousness risk.

When does Quelicin lose exclusivity?

Quelicin does not have a meaningful remaining period of new-drug exclusivity based on the age of succinylcholine and the established generic market. The relevant commercial barriers are regulatory approval, sterile injectable manufacturing, hospital purchasing, and supply reliability rather than Orange Book exclusivity.

Exclusivity issue	Assessment
New chemical entity exclusivity	Not commercially relevant
Five-year NCE period	Long expired
Three-year clinical-investigation exclusivity	Not relevant to the established product
Orphan exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance
Patent term extension	No meaningful current barrier identified
Generic competition	Established
Biosimilar competition	Not applicable
Authorized generic risk	Relevant where an innovator-linked supply arrangement exists

FDA’s Orange Book framework applies to approved drug products and listed patents, but an old injectable such as Quelicin is primarily exposed to abbreviated new drug applications, manufacturing competition, and procurement substitution rather than loss of a near-term patent right. [2]

What is the Orange Book status of Quelicin?

Quelicin is associated with FDA-approved succinylcholine chloride injection products, including NDA-based branded or branded-generic presentations. The Orange Book should be evaluated by application number and active ingredient rather than by brand name alone because multiple succinylcholine products may appear under different sponsors and labels.

The relevant Orange Book diligence questions are:

1. Whether the Quelicin application has any currently listed patents.
2. Whether any listed patent has an unexpired term.
3. Whether the product is identified as a reference listed drug for an ANDA.
4. Whether the marketed presentation differs from other approved succinylcholine injections in concentration, vial size, preservative status, or container closure.
5. Whether any exclusivity code remains active.

The practical conclusion is that Quelicin’s basic excipient system is unlikely to block generic entry. A competitor can generally pursue an equivalent injectable solution if it demonstrates pharmaceutical equivalence, bioequivalence where applicable, sterility, stability, container compatibility, and manufacturing compliance. [2,3]

Which companies are challenging Quelicin or competing with it?

Competition is broader than direct Quelicin litigation. The principal competitors are other suppliers of succinylcholine chloride injection and alternative neuromuscular blockers.

Direct product competition

Direct competition includes generic succinylcholine chloride injection manufacturers and suppliers of equivalent 20 mg/mL presentations. Market participants have included Hospira/Pfizer and other injectable-drug manufacturers with FDA-approved succinylcholine products.

The relevant competitive variables are:

• 20 mg/mL concentration.
• Single-dose versus multidose presentation.
• Preservative-free status.
• Vial size and dose visibility.
• Available supply during anesthesia-drug shortages.
• Contract pricing.
• Distributor and group-purchasing organization access.
• Product dating and cold-chain requirements.
• Packaging compatibility with automated dispensing systems.

Therapeutic competition

Succinylcholine competes with nondepolarizing neuromuscular blockers, particularly rocuronium and vecuronium. Rocuronium is the closest commercial substitute for rapid sequence intubation in many hospitals. The choice depends on onset, duration, reversal strategy, contraindications, emergency-use protocols, and clinician preference.

Product	Mechanism	Commercial position
Quelicin	Depolarizing neuromuscular blocker	Low-cost, rapid-onset option with short duration
Rocuronium	Nondepolarizing neuromuscular blocker	Broad rapid-sequence use; compatible with sugammadex reversal
Vecuronium	Nondepolarizing neuromuscular blocker	Longer procedural and intensive-care use
Cisatracurium	Nondepolarizing neuromuscular blocker	Useful where organ-independent elimination is valued
Atracurium	Nondepolarizing neuromuscular blocker	Alternative with Hofmann elimination

Quelicin’s clinical restrictions, including hyperkalemia risk, malignant hyperthermia concerns, bradycardia, and contraindications involving neuromuscular disease or major burns, constrain substitution in some patient populations. [1]

How strong is the Quelicin patent estate?

The patent estate is weak as a conventional exclusivity asset but potentially useful as a platform for narrowly focused technical filings.

Weak areas

The following concepts are unlikely to support strong broad claims on their own:

• Succinylcholine chloride in aqueous solution.
• Sodium chloride as an isotonicity agent.
• Acidic pH adjustment.
• Preservative-free composition.
• Standard glass-vial packaging.
• Basic sterile filtration and filling.

Stronger potential areas

A new entrant could pursue narrower claims around:

• Long-term stability under temperature excursions.
• Reduced succinylcholine degradation products.
• Low-extractables elastomer closures.
• Protection against oxidation or hydrolysis.
• Polymer syringes with validated compatibility.
• Ready-to-administer prefilled syringes.
• Unit-dose packaging for emergency carts.
• Automated dispensing-compatible barcoded packaging.
• Freeze-thaw or transport stability.
• Low-overfill formulations that reduce drug waste.
• Manufacturing processes that improve yield or reduce particulate burden.

The commercial strength of these claims would depend on comparative stability and manufacturing data. A patent that merely recites routine excipients would have limited blocking power. A patent tied to a demonstrated impurity, container-interaction, or shelf-life improvement could provide more credible differentiation.

What excipient strategies could create commercial opportunities?

1. Preserve the simple formulation

The lowest-risk strategy is to retain the existing excipient architecture: water for injection, sodium chloride, and controlled pH. This minimizes regulatory change, compatibility risk, and manufacturing complexity.

The commercial proposition would be reliable supply, clear labeling, and lower total procurement cost rather than a new clinical claim.

2. Develop a ready-to-use prefilled syringe

A prefilled syringe could reduce vial manipulation, preparation time, and medication-error risk in emergency and operating-room environments. The main technical issues would be:

• Drug stability in the syringe barrel.
• Elastomer and lubricant compatibility.
• Silicone oil interaction.
• Extractables and leachables.
• Needle or luer-lock compatibility.
• Sterilization method.
• Dose accuracy and overfill.
• Protection from light and temperature excursions.

A prefilled presentation could command a price premium even without new drug exclusivity. The product would need to demonstrate that the delivery system does not introduce degradation, particulate, or administration problems.

3. Create emergency-cart unit doses

Small-volume unit-dose formats could target emergency departments, ambulances, anesthesia carts, and procedural suites. A differentiated package could include:

• High-contrast strength labeling.
• Tactile or color-coded identification.
• Barcodes compatible with medication-administration systems.
• Tamper-evident packaging.
• Separate adult and pediatric workflow presentations.
• Dose-volume markings visible under low-light conditions.

These attributes are more likely to be protected through design rights, packaging patents, trademarks, and trade secrets than through broad formulation patents.

4. Improve container closure compatibility

Succinylcholine products are vulnerable to commercial disruption if the drug interacts with container components or develops unacceptable impurities during storage. A development program could compare:

• Type I glass vials.
• Cyclic olefin polymer syringes.
• Chlorobutyl and bromobutyl stoppers.
• Low-permeability closures.
• Siliconized versus nonsiliconized systems.
• Different crimp seals and overwraps.

The strongest IP opportunity would link a specific closure or packaging configuration to a measurable stability improvement.

5. Offer a preservative-free multidose alternative only with strong controls

A preserved multidose presentation could improve pharmacy convenience, but it would change the risk-benefit profile and may be less attractive in neonatal or highly safety-sensitive settings. A preservative-free multidose product would require robust antimicrobial control, in-use stability data, and clear labeling. It would not be a straightforward extension of the current presentation.

6. Build a shortage-resilient supply proposition

Injectable neuromuscular blockers have experienced supply disruptions across the market. FDA’s Drug Shortages database and hospital procurement records are therefore commercially important. [4]

A supplier could differentiate Quelicin or a competing succinylcholine product through:

• Dual-site manufacturing.
• Domestic sterile filling.
• Qualified backup stopper and vial suppliers.
• Strategic active-ingredient inventory.
• Longer dating.
• Smaller minimum order quantities.
• Allocation protocols for hospitals.
• Transparent shortage communications.
• Contractual supply guarantees.

These measures can support hospital formulary wins even when formulation differentiation is limited.

What FDA regulatory pathway applies to a new Quelicin competitor?

A chemically equivalent succinylcholine injection would generally be developed through an ANDA if a suitable reference listed drug exists. The application would need to address pharmaceutical equivalence, quality, sterility, stability, container closure, labeling, and manufacturing controls. [3]

A substantially reformulated product, such as a prefilled syringe or novel delivery system, may require a different regulatory strategy depending on the extent of formulation and device change. A 505(b)(2) pathway could be relevant where the sponsor relies in part on existing FDA findings but introduces a material change in formulation, dosage form, route, or delivery system.

The principal regulatory workstreams are:

Workstream	Key requirement
Chemistry, manufacturing, and controls	Composition, process validation, impurities, specifications
Sterility assurance	Aseptic process or validated sterilization approach
Stability	Shelf life, temperature excursions, in-use conditions
Container closure	Integrity, compatibility, extractables, leachables
Labeling	Strength, route, contraindications, warnings, storage
Human factors	Required for prefilled or device-integrated presentations
Comparative performance	Dose delivery, syringe function, and administration reliability
Postapproval controls	Change management and supply continuity

What patent litigation and Paragraph IV risks affect Quelicin?

The Paragraph IV threat is limited because the core succinylcholine product is old and generic competition is established. Any future Paragraph IV dispute would more likely concern a newly granted formulation, container, device, or manufacturing patent than the basic Quelicin composition.

Potential litigation scenarios include:

1. A branded supplier lists a new patent covering a prefilled syringe or specialized container.
2. A generic applicant challenges a narrow stability or packaging patent.
3. A sponsor alleges infringement based on a manufacturing process.
4. A competitor seeks declaratory relief against a weak formulation patent.
5. A supplier raises trade-secret claims involving sterile filling or impurity-control methods.

A basic sodium chloride and water formulation would be a poor foundation for high-value patent litigation. A formulation tied to a validated impurity reduction or a device-specific presentation would provide a more credible litigation position, although the scope would remain narrow.

No biosimilar pathway applies. A competing succinylcholine product is a generic small-molecule injectable, not a biosimilar.

What generic launch scenarios exist for Quelicin?

Low-cost vial entrant

The most direct launch is a 20 mg/mL vial matching the established formulation. This approach has the lowest development risk but faces price pressure and limited differentiation.

Premium ready-to-use entrant

A prefilled syringe or unit-dose system could target emergency medicine and anesthesia departments. The sponsor would need to justify higher pricing through workflow savings, medication-error reduction, and supply reliability.

Contract-manufacturing entrant

A sponsor could outsource sterile manufacture while owning the application, packaging, and commercial channel. This lowers capital requirements but increases dependence on the contract manufacturer’s capacity and quality system.

Regional shortage-response entrant

A manufacturer could focus on markets or hospital systems affected by unreliable supply. The opportunity may be attractive during shortage periods but less durable if additional suppliers restore availability.

Portfolio entrant

A broader anesthesia portfolio could combine succinylcholine, rocuronium, vecuronium, reversal agents, and emergency-cart products. The value would come from contracting and distribution efficiency rather than Quelicin-specific IP.

What geographic markets offer commercial opportunity?

The United States is attractive because of hospital purchasing scale, emergency airway demand, and the value of reliable sterile injectable supply. It is also highly competitive and price-sensitive.

Europe and other regulated markets offer opportunities for equivalent injectable products, but the sponsor must address country-specific marketing authorization, packaging, pharmacopoeial requirements, and procurement rules. In lower-income markets, the commercial opportunity is more dependent on local manufacturing, tender participation, temperature resilience, and price.

A global formulation strategy should avoid unnecessary excipient changes. Maintaining the same core composition while adapting vial size, labeling, language, and packaging can reduce regulatory complexity.

How does Quelicin compare with rocuronium from an excipient and commercial perspective?

Quelicin has a simpler formulation and lower intrinsic formulation complexity than many alternative neuromuscular blockers. Its value is concentrated in low cost, rapid onset, and short duration.

Rocuronium has stronger product-line opportunities because it can be positioned with prefilled syringes, reversal-agent integration, and perioperative workflow products. Quelicin can still compete where rapid offset, cost, or institutional protocols favor succinylcholine.

Factor	Quelicin	Rocuronium
Core formulation complexity	Low	Low to moderate
Preservative-free opportunity	High	High
Prefilled-syringe opportunity	High	High
Molecule-level exclusivity	None of practical significance	Generic competition established
Clinical differentiation	Rapid onset and short duration	Broad rapid-sequence use and reversal with sugammadex
Main commercial barrier	Price and supply	Price, supply, and therapeutic substitution
Best IP angle	Packaging, stability, workflow	Packaging, stability, device, workflow

Key Takeaways

• Quelicin is a 20 mg/mL preservative-free succinylcholine chloride injection.
• Its excipient system is limited to sodium chloride, water for injection, and pH adjustment.
• The formulation has low standalone patent strength because the composition is conventional and the active ingredient is old.
• No biosimilar risk applies; competition comes from generic injectable products and alternative neuromuscular blockers.
• The strongest commercial opportunities are prefilled syringes, emergency-cart unit doses, container-closure improvements, barcode-enabled packaging, and supply guarantees.
• A new entrant would generally target an ANDA for an equivalent vial product or consider a 505(b)(2) strategy for a materially differentiated presentation.
• Patent value is more plausible in stability, packaging, device integration, and manufacturing controls than in the basic excipient composition.
• Hospital contracting and shortage resilience are likely to produce more value than broad formulation exclusivity.

FAQs About Quelicin Excipient and Commercial Strategy

Is Quelicin the same as succinylcholine?

Quelicin is a branded presentation of succinylcholine chloride injection. Other FDA-approved succinylcholine injections may be pharmaceutically equivalent but can differ in manufacturer, vial size, packaging, and labeling.

Does Quelicin contain benzyl alcohol?

The labeled Quelicin formulation is preservative-free and lists sodium chloride, water for injection, and pH-adjusting agents rather than benzyl alcohol. [1]

Can a company patent a new Quelicin vial?

A vial itself is unlikely to support broad composition claims. Patentable subject matter may exist where a specific vial, stopper, seal, or overwrap produces a demonstrated stability, impurity, or container-compatibility benefit.

Is a Quelicin prefilled syringe commercially attractive?

Yes. A prefilled syringe could reduce preparation steps and support emergency and operating-room workflows. Its value would depend on stability, device reliability, procurement pricing, and evidence of operational benefit.

What is the largest market risk for a new Quelicin supplier?

The largest risks are sterile manufacturing failure, inconsistent supply, price compression, hospital-contract exclusion, and clinical substitution by rocuronium or other neuromuscular blockers.

References

1. DailyMed. (n.d.). Quelicin: Succinylcholine chloride injection, USP prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process for generic drugs. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

4. U.S. Food and Drug Administration. (n.d.). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/